invasive candidiasis – Page 2

Candida glabrata meningitis in a patient with newly diagnosed acquired immunodeficiency syndrome from Sikkim, India

mycolabadmin

A middle-aged woman in India was admitted with severe headaches and was found to have a rare fungal infection of the brain (meningitis) caused by Candida glabrata, a type of yeast. She had recently been diagnosed with AIDS and had very low immune cell counts. Although doctors tried multiple antifungal medications, the yeast showed resistance to these drugs and the patient’s condition worsened, ultimately leading to her death. This case highlights how dangerous fungal infections can be in people with severely weakened immune systems.

A Pragmatic Strategy for Improving Diagnosis of Invasive Candidiasis in UK and Ireland ICUs

mycolabadmin

Diagnosing invasive candidiasis (a serious fungal infection in ICU patients) is challenging because current blood culture tests are slow and insensitive. This paper presents a practical five-step diagnostic guide for UK and Ireland hospitals that combines risk assessment, biomarker tests, and rapid identification methods to diagnose the infection faster and more accurately. Using this strategy helps doctors avoid unnecessary antifungal drugs while ensuring seriously ill patients receive appropriate treatment quickly, ultimately improving survival rates.

Multilocus sequence typing of Candida albicans isolates from wild and farm animals from southern Italy

mycolabadmin

Researchers studied a fungal pathogen called Candida albicans found in farm and wild animals in Italy to understand how it spreads between animals and humans. They used genetic analysis to compare isolates from laying hens, wild boars, and lizards with samples from infected humans around the world. The results showed that animal isolates were genetically similar to human clinical samples, suggesting animals could serve as reservoirs for this infection. This research highlights the importance of monitoring fungal diseases in animal populations as part of understanding disease transmission between animals and people.

The efficacy of luliconazole and caspofungin on planktonic and biofilm of Candida albicans from different sources

mycolabadmin

Candida albicans, a common yeast infection organism, can form tough protective structures called biofilms that resist antifungal medications. This study tested two antifungal drugs (luliconazole and caspofungin) against Candida in both regular form and biofilm form. The results showed that while these drugs work well against regular Candida cells, they are much less effective against biofilms, which require 15-171 times higher doses to be inhibited. The strongest biofilms came from vaginal infections, suggesting that different infection types may require different treatment approaches.

Glycan microarray analysis of Candida-related antibodies in human and mice sera guides biomarker discovery and vaccine development

mycolabadmin

Researchers used a special microarray technology to identify immune responses in blood samples from people infected with Candida yeast. They found that early infections trigger antibodies against certain sugar structures, while later infections produce different antibodies. Three specific sugar molecules showed promise as markers for diagnostic tests and vaccine development against dangerous yeast infections.

Invasive Candidiasis in Contexts of Armed Conflict, High Violence, and Forced Displacement in Latin America and the Caribbean (2005–2025)

mycolabadmin

Invasive candidiasis, a serious fungal blood infection caused by Candida species, is a major health crisis in Latin America and the Caribbean with death rates reaching 60% in vulnerable populations. The disease is worsening in areas affected by armed conflict, violence, and displacement where poor living conditions, overcrowding, malnutrition, and lack of healthcare create ideal conditions for the infection to develop and spread. Antifungal drugs are often unavailable or too expensive, and drug-resistant strains of Candida are becoming increasingly common, making treatment extremely challenging in these regions.

Candida vulturna, the Next Fungal Menace? A Narrative Review

mycolabadmin

Candida vulturna is a newly identified fungus that causes serious bloodstream infections, particularly in newborns and hospitalized patients in tropical regions. Unlike many common fungal infections, it resists several antifungal medications, though it remains susceptible to certain antibiotics called echinocandins. Scientists have documented 94 cases worldwide, including three hospital outbreaks, and the infection has a relatively low death rate of 18%. Accurate identification requires genetic testing since standard hospital laboratory tests often misidentify this pathogen.

Changing Climate, Changing Candida: Environmental and Social Pressures on Invasive Candidiasis and Antifungal Resistance in Latin America

mycolabadmin

Invasive fungal infections caused by Candida species are becoming increasingly common and dangerous in Latin American hospitals, with newer strains showing resistance to multiple antifungal drugs. Rising temperatures from climate change and widespread use of fungicides in agriculture appear to be selecting for these resistant fungi. Most hospitals in the region lack advanced diagnostic tools to quickly identify which fungal strain is causing infection, leading to delayed and sometimes inappropriate treatment. Implementing better diagnostic access, stricter antifungal use policies, and coordinated surveillance programs across the region could help control this growing public health problem.

Candida krusei Empyema: A Lung Transplant Case and Systematic Review of the Literature

mycolabadmin

Candida krusei is a dangerous yeast that causes a serious lung infection called empyema, where pus collects around the lungs. This infection is particularly difficult to treat because the yeast is resistant to common antifungal drugs like fluconazole and can form protective biofilms. This systematic review identified only ten cases of this rare infection in the medical literature, showing how uncommon but serious it is, and found that patients need aggressive treatment with multiple antifungal medications combined with surgical drainage to survive.

Renaming Candida glabrata—A case of taxonomic purity over clinical and public health pragmatism

mycolabadmin

Candida glabrata is a common yeast infection that causes serious illnesses in humans, affecting millions of people worldwide. Scientists have recently proposed renaming it to Nakaseomyces glabrata for technical taxonomic reasons. However, this article argues against the change because it would create confusion for doctors, complicate treatment instructions on medications, disrupt disease tracking systems, and make it harder for patients to understand their conditions. Keeping the familiar name Candida glabrata is more practical and helpful for patient care and public health than strict adherence to taxonomic classification rules.

Research Keyword: invasive candidiasis